Stoke Therapeutics, Inc.
As of Oct 22, 2026, Stoke Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $25.70, 33.0% below its 52-week high and below its 200-day average, which is falling.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is STOK early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
STOK among Biotechnology266th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …266 | STOK | Stage 4 · wk 6 | 36 | −1.6% |
Stoke Therapeutics: quick answers
What stage is Stoke Therapeutics in?
As of Oct 22, 2026, Stoke Therapeutics (STOK) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean
Is Stoke Therapeutics in an uptrend?
No. Stoke Therapeutics is in a Stage 4 downtrend. It trades 17.4% below its 200-day average, which is falling.
How far is Stoke Therapeutics from its 52-week high?
Stoke Therapeutics closed at $25.70 on Oct 22, 2026, 33.0% below its 52-week high of $38.35. Its 52-week low is $22.37.
How has Stoke Therapeutics performed over the past year?
As of Oct 22, 2026, Stoke Therapeutics is down 25.9% over the past year and down 16.8% so far in 2026.
Which sector and industry is Stoke Therapeutics in?
Stoke Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.